RT info:eu-repo/semantics/article
T1 Inhibition of Sarco-Endoplasmic Reticulum Ca2+ ATPase Extends the Lifespan in C. elegans Worms
A1 García-Casas, Paloma
A1 Arias-del-Val, Jessica
A1 Alvarez-Illera, Pilar
A1 Fonteriz, Rosalba I.
A1 Montero Zoccola, María Teresa
A1 Álvarez Martín, Javier
K1 C. elegans, lifespan, Ca2C signaling, SERCA, thapsigargin, aging, calcium, endoplasmic reticulum
AB The sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) refills the endoplasmic reticulum (ER) with Ca2+ up to the millimolar range and is therefore the main controller of the ER [Ca2+] level ([Ca2+]ER), which has a key role in the modulation of cytosolic Ca2+ signaling and ER-mitochondria Ca2+ transfer. Given that both cytosolic and mitochondrial Ca2+ dynamics strongly interplay with energy metabolism and nutrient sensitive pathways, both of them involved in the aging process, we have studied the effect of SERCA inhibitors on lifespan in C. elegans. We have used thapsigargin and 2,5-Di-tert-butylhydroquinone (2,5-BHQ) as SERCA inhibitors, and the inactive analog 2,6-Di-tert-butylhydroquinone (2,6-BHQ) as a control for 2,5-BHQ. Every drug was administered to the worms either directly in the agar or via an inclusion compound with g-cyclodextrin. The results show that 2,6-BHQ produced a small but significantincrease in survival, perhaps because of its antioxidant properties. However, 2,5-BHQ produced in all the conditions a much higher increase in lifespan, and the potent and specific SERCA inhibitor thapsigargin also extended the lifespan. The effects of 2,5-BHQ and thapsigargin had a bell-shaped concentration dependence, with a maximum effect at a certain dose and smaller or even toxic effects at higher concentrations. Our data show therefore that submaximal inhibition of SERCA pumps has a pro-longevity effect, suggesting that Ca2+ signaling plays an important role in the aging process and that it could be a promising novel target pathway to act on aging.
PB Frontiers
SN 1663-9812
YR 2018
FD 2018
LK https://uvadoc.uva.es/handle/10324/66092
UL https://uvadoc.uva.es/handle/10324/66092
LA eng
NO Frontiers in Pharmacology, Junio 2018, 9, 669
NO Producción Científica
DS UVaDOC
RD 18-nov-2024